{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:52:37Z","timestamp":1788339157645,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010803","name":"Department of Biotechnology","doi-asserted-by":"crossref","award":["BT\/PR6806\/GBD\/27\/480\/2012"],"award-info":[{"award-number":["BT\/PR6806\/GBD\/27\/480\/2012"]}],"id":[{"id":"10.13039\/501100010803","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010892","name":"Department of Science and Technology","doi-asserted-by":"crossref","award":["SB\/YS\/LS-61\/2014"],"award-info":[{"award-number":["SB\/YS\/LS-61\/2014"]}],"id":[{"id":"10.13039\/501100010892","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.neulet.2016.06.011","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T17:41:47Z","timestamp":1465234907000},"page":"225-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["L-DOPA treatment in MPTP-mouse model of Parkinson\u2019s disease potentiates homocysteine accumulation in substantia nigra"],"prefix":"10.1016","volume":"628","author":[{"given":"Nivedita","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Khairujjaman","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajib","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarendranath","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabanum","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-5367","authenticated-orcid":false,"given":"Anupom","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.neulet.2016.06.011_bib0005","first-page":"61393","article-title":"Parkinson's disease","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neulet.2016.06.011_bib0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","article-title":"Levodopa in the treatment of Parkinson's disease","volume":"16","author":"Schapira","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neulet.2016.06.011_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neulet.2016.06.011_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pneurobio.2011.06.005","article-title":"L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease","volume":"94","author":"Lipski","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neulet.2016.06.011_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/biof.71","article-title":"Homocysteine metabolism and its relation to health and disease","volume":"36","author":"Williams","year":"2010","journal-title":"Biofactors"},{"key":"10.1016\/j.neulet.2016.06.011_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lfs.2015.07.031","article-title":"The potential physiological crosstalk and interrelationship between two sovereign endogenous amines, melatonin and homocysteine","volume":"139","author":"Paul","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.neulet.2016.06.011_bib0035","first-page":"2498","article-title":"Parkinson study group. Levodopa and the progression of Parkinson\u2019s disease","volume":"9","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2016.06.011_bib0040","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.lfs.2005.02.014","article-title":"Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease","volume":"77","author":"Isobe","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.neulet.2016.06.011_bib0045","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbagen.2016.06.018","article-title":"L-DOPA-induced hyperhomocysteinemia in Parkinson\u2019s disease: elephant in the room","volume":"1860","author":"Paul","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neulet.2016.06.011_bib0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/092986710790149774","article-title":"Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment","volume":"17","author":"Zoccolella","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neulet.2016.06.011_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neulet.2016.06.011_bib0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson\u2019s disease","volume":"80","author":"Duan","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2016.06.011_bib0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","article-title":"Effects of homocysteine on the dopaminergic system and behavior in rodents","volume":"26","author":"Lee","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neulet.2016.06.011_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2005.12.073","article-title":"Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats","volume":"1075","author":"Chandra","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2016.06.011_bib0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2006.05.040","article-title":"Homocysteine serum levels and MTHFH C677T genotype in patients with Parkinson's disease, with and without levopoda therapy","volume":"248","author":"Todorovic","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neulet.2016.06.011_bib0080","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","article-title":"The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats","volume":"112","author":"Nissinen","year":"2005","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neulet.2016.06.011_bib0085","doi-asserted-by":"crossref","first-page":"e50496","DOI":"10.1371\/journal.pone.0050496","article-title":"Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model","volume":"7","author":"Shin","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neulet.2016.06.011_bib0090","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1073\/pnas.0813361106","article-title":"Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2016.06.011_bib0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-079X.2009.00713.x","article-title":"Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents","volume":"47","author":"Borah","year":"2009","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.neulet.2016.06.011_bib0100","first-page":"47","article-title":"Chronic exposure of homocysteine in mice contributes to dopamine loss by enhancing oxidative stress in nigrostriatum and produces behavioral phenotypes of Parkinson\u2019s disease","volume":"6","author":"Bhattacharjee","year":"2016","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.neulet.2016.06.011_bib0105","series-title":"Brain Microdissection Techniques","author":"Palkovits","year":"1983"},{"key":"10.1016\/j.neulet.2016.06.011_bib0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2013.09.024","article-title":"10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits","volume":"231","author":"Elseweidy","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.neulet.2016.06.011_bib0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2001.7726","article-title":"L-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-Methyltransferase","volume":"171","author":"Zhao","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2016.06.011_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/glia.20185","article-title":"Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons","volume":"51","author":"Huang","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.neulet.2016.06.011_bib0125","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.pnpbp.2005.06.025","article-title":"The central nervous system in animal models of hyperhomocysteinemia","volume":"29","author":"Troen","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neulet.2016.06.011_bib0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease","volume":"75","author":"M\u00fcller","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.neulet.2016.06.011_bib0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00726-003-0026-8","article-title":"Homocysteine and oxidative stress","volume":"25","author":"Perna","year":"2003","journal-title":"Amino Acids"},{"key":"10.1016\/j.neulet.2016.06.011_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.55782\/ane-2006-1619","article-title":"Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors","volume":"66","author":"Zieminska","year":"2006","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.neulet.2016.06.011_bib0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.expneurol.2009.09.027","article-title":"Excitotoxicity, and programmed cell death in Parkinson disease","volume":"220","author":"Caudle","year":"2009","journal-title":"Exp. Neurol."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0304394016304104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0304394016304104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:19:54Z","timestamp":1718623194000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394016304104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":29,"alternative-id":["S0304394016304104"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2016.06.011","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-DOPA treatment in MPTP-mouse model of Parkinson\u2019s disease potentiates homocysteine accumulation in substantia nigra","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.neulet.2016.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}